跳转至内容
Merck
CN

1556008

USP

醋酸泼尼松龙

United States Pharmacopeia (USP) Reference Standard

别名:

醋酸泼尼松龙, 1,4-孕甾二烯-11β,17α,21-三醇-3,20-二酮 21-醋酸酯, 11β,17α,21-三羟基-1,4-孕甾二烯-3,20-二酮 21-醋酸酯, 21-乙酰氧基-1,4-孕甾二烯-11β,17α-二醇-3,20-二酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H30O6
CAS号:
分子量:
402.48
Beilstein:
3111798
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

prednisolone

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])CC[C@]4(O)C(=O)COC(C)=O

InChI

1S/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1

InChI key

LRJOMUJRLNCICJ-JZYPGELDSA-N

基因信息

human ... NR3C1(2908)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

相关产品

产品编号
说明
价格

象形图

Health hazard

警示用语:

Danger

危险声明

危险分类

Repr. 1B

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Antigoni Koukkoulli et al.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 253(1), 99-106 (2014-10-12)
To report on long-term outcomes of mitomycin C (MMC)-augmented needle revision of failing deep sclerectomy (DS) blebs. Retrospective database search of all needle revisions with MMC for DS blebs between 2002 and 2008 was conducted. Sixty-six eyes of 66 patients
Rohit Shetty et al.
Indian journal of ophthalmology, 62(9), 923-926 (2014-11-06)
To study the safety and efficacy of sutureless femtosecond anterior lamellar keratoplasty (FALK) in patients with corneal stromal opacities. Eleven eyes of 11 consecutive patients with corneal stromal opacities involving < 250 μ due to various pathologies were included in
Oscar A Candia et al.
Experimental eye research, 128, 114-116 (2014-10-12)
We have previously shown that tissue plasminogen activator (tPA) injected in the vitreous of sheep, reduced or prevented the elevation of the intraocular pressure (IOP) normally produced by the instillation of 1% prednisolone. We now report the effect of tPA
Rohit Shetty et al.
American journal of ophthalmology, 159(3), 419-425 (2014-12-03)
To evaluate the effect of keratoconus cone location on the change in refractive outcomes, corneal aberrations, and biomechanics after combined topography-guided photorefractive keratectomy (PRK) and collagen cross-linking (CXL). Prospective, comparative case series. Topography-guided PRK was performed followed by accelerated CXL
Wool Suh et al.
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 29(7), 646-651 (2013-04-30)
To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU). Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwent trabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门